Package Leaflet: Information for the User
Ticagrelor Vivanta 60 mg film-coated tablets EFG
Ticagrelor Vivanta 90 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
5 Conservation of Ticagrelor Vivanta
What is Ticagrelor Vivanta
This medicine contains the active substance ticagrelor. It belongs to a group of medicines called antiplatelet agents.
What Ticagrelor Vivanta is used for
Ticagrelor Vivanta 60 mg film-coated tablets EFG
Ticagrelor in combination with acetylsalicylic acid (another antiplatelet agent) should only be used in adults. You have been prescribed this medicine because you have had:
This medicine reduces the risk of you having another heart attack, a stroke, or dying from a heart or blood vessel disease.
Ticagrelor Vivanta 90 mg film-coated tablets EFG
Ticagrelor in combination with acetylsalicylic acid (another antiplatelet agent) should only be used in adults. You have been prescribed this medicine because you have had:
This medicine reduces the risk of you having another heart attack, a stroke, or dying from a heart or blood vessel disease.
How Ticagrelor Vivanta works
Ticagrelor works on cells called ‘platelets’ (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to block tiny holes in blood vessels that are cut or damaged.
However, platelets can also form clots inside damaged blood vessels in the heart and brain. This can be very dangerous because:
Ticagrelor helps prevent platelets from clumping together. This reduces the chance of a blood clot forming that could reduce blood flow.
Do not take Ticagrelor Vivanta if:
Do not take ticagrelor if you are in any of the above situations. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before taking ticagrelor if:
If any of the above applies to you (or if you are unsure), consult your doctor or pharmacist before taking this medicine.
If you are taking ticagrelor and heparin:
Children and adolescents
Ticagrelor is not recommended for children and adolescents under 18 years of age.
Other medicines and Ticagrelor Vivanta
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This is because ticagrelor may affect the way some medicines work and some medicines may affect ticagrelor.
Tell your doctor or pharmacist if you are taking any of the following medicines:
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase the risk of bleeding:
Tell your doctor that, because you are taking ticagrelor, you may have a higher risk of bleeding if your doctor gives you fibrinolytics, often referred to as ‘clot dissolvers’, such as streptokinase or alteplase.
Pregnancy and breastfeeding
Ticagrelor should not be used if you are pregnant or may become pregnant. Women should use appropriate contraceptive methods to avoid pregnancy while taking this medicine.
Consult your doctor before taking this medicine if you are breastfeeding. Your doctor will explain the benefits and risks of taking ticagrelor during this time.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
Driving and using machines
Ticagrelor is unlikely to affect your ability to drive or use machines. If you feel dizzy or confused while taking this medicine, be careful while driving or using machines.
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
How much to take
Ticagrelor Vivanta 60 mg film-coated tablets EFG
Ticagrelor Vivanta 90 mg film-coated tablets EFG
Taking Ticagrelor Vivanta with other blood clotting medicines
Your doctor will also usually prescribe acetylsalicylic acid. This is a substance found in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75-150 mg daily).
How to take Ticagrelor Vivanta
If you have difficulty swallowing the tablet
If you have difficulty swallowing the tablet, you can crush it and mix it with water as follows:
If you are in the hospital, this tablet may be given to you mixed with a little water through a tube in your nose (nasogastric tube).
If you take more Ticagrelor Vivanta than you should
If you take more ticagrelor than you should, consult your doctor or go to the hospital immediately. Bring the medicine pack with you. You may have a higher risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Ticagrelor Vivanta
If you stop taking Ticagrelor Vivanta
Do not stop taking ticagrelor without consulting your doctor. Take this medicine regularly and for as long as your doctor tells you. If you stop taking ticagrelor, you may increase the risk of having another heart attack or stroke, or dying from a heart or blood vessel disease.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. With this medicine, the following side effects may occur:
Ticagrelor affects blood clotting, so most side effects are related to bleeding. Bleeding can occur anywhere in the body. Some level of bleeding is common (such as bruising and nosebleeds). Serious bleeding is uncommon but can be life-threatening.
Tell your doctor immediately if you notice any of the following - you may need urgent medical treatment:
Tell your doctor if you notice any of the following:
Other possible side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use https://www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister pack and carton after EXP/CAD. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Ticagrelor Vivanta 60 mg film-coated tablets EFG
Each film-coated tablet contains 60 mg of ticagrelor.
Ticagrelor Vivanta 90 mg film-coated tablets EFG
Each film-coated tablet contains 90 mg of ticagrelor.
Tablet core:mannitol (E421), low-substituted hydroxypropylcellulose, calcium hydrogen phosphate dihydrate, hydroxypropylcellulose (E463) (contains silica), magnesium stearate (E470b).
Tablet film coating:
Ticagrelor Vivanta 60 mg film-coated tablets EFG
hypromellose 2910 (E464), titanium dioxide (E171), talc (E553b), macrogol 400 (E1521), yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172)
Ticagrelor Vivanta 90 mg film-coated tablets EFG
hypromellose 2910 (E464), titanium dioxide (E171), macrogol 400 (E1521), talc (E553b), yellow iron oxide (E172).
Product appearance and container contents
Ticagrelor Vivanta 60 mg film-coated tablets EFG
Film-coated tablets, round, biconvex, pink (approximately 8 mm in diameter), engraved with "60 & M" on one side and smooth on the other.
Ticagrelor Vivanta 90 mg film-coated tablets EFG
Film-coated tablets, biconvex, round, yellow (approximately 9 mm in diameter), engraved with "90 & M" on one side and smooth on the other.
Ticagrelor Vivanta is available in:
Ticagrelor 60 mg
Ticagrelor 90 mg
Only some pack sizes may be marketed.
Marketing authorization holder and manufacturer
Vivanta Generics s.r.o
Trtinova 260/1, Cakovice,
19600, Prga 9
Czech Republic.
Manufacturer:
MSN Labs Europe Ltd.,
KW20A Corradino Park,
Paola, PLA3000,
Malta
or
Pharmadox Healthcare Ltd.,
KW20A Kordin Industrial Park,
Paola, PLA3000,
Malta
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Local representative:
Mabo-Farma S.A.
Calle Vía de los Poblados 3, Edificio 6
28033 Madrid
Spain
This medication is authorized in the member states of the European Economic Area under the following names:
Germany: Ticagrelor Vivanta 60 mg film-coated tablets
Ticagrelor Vivanta 90 mg film-coated tablets
Cyprus: Ticagrelor MSN 60 mg, film-coated tablets
Ticagrelor MSN 90 mg, film-coated tablets
Denmark: Ticagrelor Vivanta
Spain: Ticagrelor Vivanta 60 mg film-coated tablets EFG
Ticagrelor Vivanta 90 mg film-coated tablets EFG
Finland: Ticagrelor Vivanta 60 mg film-coated tablets
Ticagrelor Vivanta 90 mg film-coated tablets
Hungary: Ticagrelor Vivanta 60 mg film-coated tablets
Ticagrelor Vivanta 90 mg film-coated tablets
Norway: Ticagrelor Vivanta
Netherlands: Ticagrelor Vivanta 60 mg film-coated tablets
Ticagrelor Vivanta 90 mg film-coated tablets
Portugal: Ticagrelor Vivanta
Sweden: Ticagrelor Vivanta 60 mg film-coated tablets
Ticagrelor Vivanta 90 mg film-coated tablets
Date of the last revision of this prospectus: February 2024
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob/